[CAS NO. 29477-83-6] Narciclasine

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [29477-83-6]

Catalog

HY-16563

Brand

MCE

CAS

29477-83-6

DESCRIPTION [29477-83-6]

Overview

MDL	MFCD01729949
Molecular Weight	307.26
Molecular Formula	C14H13NO7
SMILES	O=C1N[C@@]2([H])[C@H](O)[C@H](O)[C@@H](O)C=C2C3=C1C(O)=C4C(OCO4)=C3

For research use only. We do not sell to patients.

9 Publications Citing Use of MCE

Summary

Narciclasine is a plant growth modulator. Narciclasine modulates the Rho/Rho kinase/LIM kinase/cofilin signaling pathway, greatly increasing GTPase RhoA activity as well as inducing actin stress fiber formation in a RhoA-dependent manner.

IC50 & Target

ROCK

In Vitro

Narciclasine activates Rho and stress fibers in glioblastoma multiforme cells. The mean IC ₅₀ of ~50 nM calculated on the 6 human glioblastoma multiforme (U373, Hs683, GL19, GL5, GL16, GL17), The mean IC ₅₀ value of 47 nM for Narciclasine across a panel of 60 cancer cell lines ^[1] . Bioassay-guided fractionation of the A. belladonna extract resulted in the identification of lycorine as the bio-active compound. The IC ₅₀ measured for radicle growth inhibition is 0.1 µM for Narciclasine ^[2] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

The i.v. regimen of Narciclasine at 1 mg/kg significantly (P=0.02) increases the survival of GL19 glioblastoma multiforme-bearing mice. Narciclasine when given orally at the same dose five times a week for 5 consecutive weeks also significantly increases animal survival in this model (P=0.008). Oral treatment with Narciclasine at 1 mg/kg significantly increases the survival (P=0.004) of Hs683 glioblastoma multiforme-bearing mice. Increasing the number of doses administered per week does not increase the survival of these Hs683 glioblastoma multiforme-bearing mice. Narciclasine appears to show similar increased survival in these models to temozolomide but at appreciable lower doses and following both oral and i.v. administration ^[1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Appearance

Solid

Source

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : ≥ 26 mg/mL ( 84.62 mM )

* "≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.2546 mL	16.2729 mL	32.5457 mL
5 mM	0.6509 mL	3.2546 mL	6.5091 mL
10 mM	0.3255 mL	1.6273 mL	3.2546 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 1.67 mg/mL (5.44 mM); Clear solution
2.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 1.67 mg/mL (5.44 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 1.67 mg/mL (5.44 mM); Clear solution

* All of the co-solvents are available by MCE.

References

Synonyms

[1,3]Dioxolo[4,5-j]phenanthridin-6(2H)-one, 3,4,4a,5-tetrahydro-2,3,4,7-tetrahydroxy-, (2S,3R,4S,4aR)-

[1,3]Dioxolo[4,5-j]phenanthridin-6(2H)-one, 3,4,4a,5-tetrahydro-2,3,4,7-tetrahydroxy-, [2S-(2α,3β,4β,4aβ)]-

(2S,3R,4S,4aR)-3,4,4a,5-Tetrahydro-2,3,4,7-tetrahydroxy[1,3]dioxolo[4,5-j]phenanthridin-6(2H)-one

Narciclasine

Lycoricidinol

(+)-Lycoricidinol

(+)-Narciclasine

NSC 266535